Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04B UROLOGICALS
G04BD Drugs for urinary frequency and incontinence
G04BD10 Darifenacin
D01699 Darifenacin hydrobromide (JAN/USAN) <US>
USP drug classification [BR:br08302]
Genitourinary Agents
Antispasmodics, Urinary
Cholinergic Muscarinic Antagonists
Darifenacin
D01699 Darifenacin hydrobromide (JAN/USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01491 Muscarinic cholinergic receptor antagonist
DG00482 Darifenacin
D01699 Darifenacin hydrobromide
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00482 Darifenacin
D01699 Darifenacin hydrobromide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00482 Darifenacin
D01699 Darifenacin hydrobromide
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Acetylcholine (muscarinic)
CHRM3
D01699 Darifenacin hydrobromide (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01699
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01699
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01699
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01699
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D01699
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01491 Muscarinic cholinergic receptor antagonist
DG00482 Darifenacin
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00482 Darifenacin
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00482 Darifenacin